| Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction. | |
| | |
MedLine Citation:
|
PMID: 21062392 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVES: • To assess the effect of α1-D/A adrenoceptor antagonist naftopidil on patients with neurogenic lower urinary tract dysfunction (NLUTD) and voiding difficulty. • To explore the effectiveness of naftopidil in these patients by using urodynamic variables, including pressure flow study (PFS), and to find good and simple parameters (International Prostate Symptom Score (IPSS), Post-void residual urine (PVR), and uroflowmetry (UFM) parameters) as substitution of PFS for predicting the effect of naftopidil. PATIENTS AND METHODS: • The main inclusion and exclusion criteria were, IPSS ≥8, voiding symptoms with IPSS ≥5, IPSS-quality of life (QOL) ≥2, PVR ≥50 mL, and without prostatic enlargement ≥ 20 mL. • After initial assessment, patients were stepwisely administered for 12 weeks with the following: placebo for 2 weeks, naftopidil 25 mg/day for 2 weeks, naftopidil 50 mg/day for 2 weeks, and naftopidil 75 mg/day for 6 weeks. At the end of both placebo and 6 weeks' naftopidil 75 mg/day, their IPSS, UFM, PVR, and PFS were assessed. • A total of 82 Japanese patients (men 40, women 42) with lower urinary tract symptoms complicated by NLUTD, with a mean age of 63.9 years, were included from private or institutional clinics. • The lesions were spinal cord 42, and peripheral nervous system 40. The spinal cord lesions were all lumbar spine (injury or lumbar canal stenosis). RESULTS: • In all patients, pressure at maximum urinary flow rate (P(det) Q(max) ) in PFS significantly decreased (P < 0.05), and maximum urinary flow rate in UFM significantly increased (P < 0.01). Analysis of data for men and for women also showed a significant decrease in PVR, %PVR, and total IPSS score. • The degree of improvement of voided volume, PVR (%), and IPSS in patients with PVR <300 mL was significantly greater than those in patients with PVR ≥300 mL. • The degree of improvement of P(det) Q(max) in PFS, and IPSS in patients with bladder contractility was significantly greater than that in patients without bladder contractility. CONCLUSIONS: • α1-D/A adrenoceptor antagonist naftopidil has a significant effect on both symptoms and urodynamic variables of patients of both genders with NLUTD in Japan. • PVR <300 mL and bladder contractility are predictive factors for the efficacy of naftopidil on patients with NLUTD. |
| | |
Authors:
|
Masayuki Takeda; Yukio Homma; Isao Araki; Hidehiro Kakizaki; Tomonori Yamanishi; Takashi Yokota; Momokazu Gotoh; Yasuhiko Igawa; Narihito Seki; Mineo Takei; Masaki Yoshida; Kimio Sugaya; Osamu Nishizawa; |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-11-09 |
Journal Detail:
|
Title: BJU international Volume: 108 ISSN: 1464-410X ISO Abbreviation: BJU Int. Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100886721 Medline TA: BJU Int Country: England |
Other Details:
|
Languages: eng Pagination: 100-7 Citation Subset: IM |
Copyright Information:
|
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. |
Affiliation:
|
Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan. matakeda@yamanashi.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of ORPs in sterol transport from plasma membrane to ER and lipid droplets in mammalian cells.
Next Document: Survival after prostate brachytherapy in patients aged 60 years and younger.